A couple of months ago, Intellia’s leader and founder Nessan Bermingham, Ph.D., left the CRISPR company, but we knew not where.
Today, we found out, and there is little surprise on this occasion as Bermingham has returned full circle, back at Atlas Ventures, the firm that also helped launch Intellia, one of a handful of U.S. biotechs hoping to make good on the early promise of CRISPR gene editing. He first started at the VC firm back in 2002.
Nessan will now be involved “with the formation and leadership of ground-breaking new biotechnology companies as part of the Atlas platform,” the firm said in a brief statement.
“I am thrilled to be working with Atlas again as we translate cutting-edge scientific advances into medicines for patients in need and build great companies,” says Bermingham.
Bermingham co-founded Intellia with Atlas back in 2014, leading the company from its seed investment and incubation at Atlas through to its $108 million IPO.
He first joined Atlas in 2002 and worked on multiple Atlas portfolio companies across various stages
“Nessan is a relentless entrepreneur and operator who has proven his ability to build breakthrough biotech companies from the ground up,” said Jean François Formela, partner at Atlas.
“We are excited to welcome him back to Atlas and look forward to creating transformational new companies with him.”
By Ben Adams
Source: Fierce Biotech
The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.
Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.
